SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
COCH reported Third Quarter 2026 results. The price and volatility reaction is pending.
COCHearnings

Earnings reactions, page 6

Envoy Medical, Inc. (COCH) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Net revenue was $66 thousand for the three months ended September 30, 2026, compared to $42 thousand for the three months ended September 30, 2025.
  • R&D expenses were $3,077 thousand for the three months ended September 30, 2026, compared to $2,700 thousand for the three months ended September 30, 2025.
  • Sales and marketing expenses were $157 thousand for the three months ended September 30, 2026, compared to $405 thousand for the three months ended September 30, 2025.
  • General and administrative expenses were $2,125 thousand for the three months ended September 30, 2026, compared to $1,999 thousand for the three months ended September 30, 2025.
  • Net loss attributable to common stockholders was $5,240 thousand, or $0.50 per basic and diluted share for the three months ended September 30, 2026.
  • Cash was approximately $14,570 thousand as of September 30, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →